Answers are grounded in this paper and cite their sources.
Real-world evaluation demonstrates automated diabetic retinopathy detection in clinical cohorts, highlighting an alternative to manual ophthalmologist screening.
Screening for diabetic retinopathy (DR) by ophthalmologists is costly and labour-intensive. Artificial Intelligence (AI) for automated DR detection could be a clinically and economically alternative. We assessed the performance of a confocal fundus imaging system (DRSplus, Centervue SpA), coupled with an AI algorithm (RetCAD, Thirona B.V.) in a real-world setting.
No takes yet. Share an insight, caveat, or question.
Piatti et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: